PriceTargets.com logo

Soleno Therapeutics - SLNO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $110.62
  • Forecasted Upside: 186.87%
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 2 Strong Buy Ratings
$38.56 As of 01/30/2026 05:00 PM ET
▼ -1.99 (-4.91%)

This chart shows the closing price for SLNO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Soleno Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLNO

Analyst Price Target is $110.62
▲ +186.87% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $110.62, with a high forecast of $145.00 and a low forecast of $60.00. The average price target represents a 186.87% upside from the last price of $38.56.

This chart shows the closing price for SLNO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Soleno Therapeutics. This rating has held steady since November 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 2 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 2 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/20/2026Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$106.00 ➝ $114.00
1/20/2026HC WainwrightReiterated RatingBuy ➝ Buy$110.00 ➝ $120.00
1/13/2026Robert W. BairdSet Target$107.00
1/12/2026Wolfe ResearchSet Target$60.00
1/12/2026Wolfe ResearchReiterated RatingOutperform ➝ Outperform
1/5/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
11/18/2025Wolfe ResearchInitiated CoverageOutperform$75.00
11/17/2025Wolfe ResearchUpgradeStrong-Buy
11/5/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$123.00 ➝ $106.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025The Goldman Sachs GroupSet TargetBuy$125.00
10/7/2025The Goldman Sachs GroupInitiated CoverageBuy$125.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/10/2025Lifesci CapitalUpgradeStrong-Buy
8/27/2025GuggenheimReiterated RatingBuy ➝ Buy$106.00
8/20/2025Wells Fargo & CompanyInitiated CoverageOverweight$123.00
8/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $110.00
8/7/2025TD CowenReiterated RatingBuy ➝ Buy
8/7/2025GuggenheimBoost TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025OppenheimerBoost TargetOutperform ➝ Outperform$105.00 ➝ $110.00
7/11/2025Robert W. BairdSet TargetOutperform ➝ Outperform$105.00 ➝ $121.00
6/23/2025TD CowenInitiated CoverageBuy
6/23/2025TD CowenInitiated CoverageBuy$110.00
5/8/2025GuggenheimBoost TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$102.00 ➝ $105.00
4/24/2025Piper SandlerBoost TargetOverweight ➝ Overweight$93.00 ➝ $145.00
4/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
3/31/2025HC WainwrightBoost TargetBuy ➝ Buy$70.00 ➝ $100.00
3/28/2025GuggenheimReiterated RatingBuy ➝ Buy$70.00 ➝ $81.00
3/28/2025Stifel NicolausBoost TargetBuy ➝ Buy$74.00 ➝ $108.00
3/27/2025UBS GroupSet Target$105.00
3/27/2025LaidlawBoost TargetBuy ➝ Buy$75.00 ➝ $105.00
3/27/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$67.00 ➝ $123.00
3/27/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$72.00 ➝ $102.00
3/5/2025Stifel NicolausInitiated CoverageBuy$74.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
2/4/2025Lifesci CapitalUpgradeStrong-Buy
12/2/2024Stifel NicolausReiterated RatingBuy$74.00
12/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
12/2/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$72.00 ➝ $72.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
10/28/2024OppenheimerBoost TargetOutperform ➝ Outperform$65.00 ➝ $73.00
10/1/2024Stifel NicolausBoost TargetBuy ➝ Buy$59.00 ➝ $74.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
9/3/2024HC WainwrightInitiated CoverageBuy$70.00
8/12/2024OppenheimerBoost TargetOutperform ➝ Outperform$59.00 ➝ $65.00
7/31/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/13/2024OppenheimerLower TargetOutperform ➝ Outperform$65.00 ➝ $59.00
5/10/2024Robert W. BairdUpgradeStrong-Buy
5/10/2024Robert W. BairdInitiated CoverageOutperform$72.00
2/5/2024Piper SandlerInitiated CoverageOverweight$93.00
1/23/2024Stifel NicolausInitiated CoverageBuy$63.00
1/2/2024OppenheimerBoost TargetOutperform ➝ Outperform$44.00 ➝ $47.00
11/21/2023GuggenheimReiterated RatingBuy$40.00
9/26/2023OppenheimerBoost Target$14.00 ➝ $39.00
9/26/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$19.00 ➝ $35.00
9/15/2023OppenheimerBoost TargetOutperform ➝ Outperform$8.00 ➝ $14.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$19.00
7/11/2023Cantor FitzgeraldReiterated RatingOverweight
3/24/2023OppenheimerReiterated RatingOutperform$8.00
11/17/2022OppenheimerBoost Target$8.00
3/3/2021OppenheimerReiterated RatingBuy$120.00
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2025
  • 22 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2025
  • 28 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 22 very positive mentions
  • 43 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
Mentions as of
10/4/2025
  • 11 very positive mentions
  • 34 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 29 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 13 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 16 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 16 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More

Today's Range

Now: $38.56
Low: $37.95
High: $40.75

50 Day Range

MA: $46.58
Low: $38.56
High: $52.68

52 Week Range

Now: $38.56
Low: $37.95
High: $90.32

Volume

3,267,587 shs

Average Volume

1,585,842 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Soleno Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Soleno Therapeutics in the last twelve months: Cantor Fitzgerald, Guggenheim, HC Wainwright, Laidlaw, Lifesci Capital, Oppenheimer Holdings, Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research.
View the latest analyst ratings for SLNO.

What is the current price target for Soleno Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Soleno Therapeutics in the last year. Their average twelve-month price target is $110.62, suggesting a possible upside of 186.9%. Piper Sandler has the highest price target set, predicting SLNO will reach $145.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $60.00 for Soleno Therapeutics in the next year.
View the latest price targets for SLNO.

What is the current consensus analyst rating for Soleno Therapeutics?

Soleno Therapeutics currently has 1 sell rating, 12 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLNO will outperform the market and that investors should add to their positions of Soleno Therapeutics.
View the latest ratings for SLNO.

What other companies compete with Soleno Therapeutics?

Other companies that are similar to Soleno Therapeutics include Femasys, Immunovant, Glaukos, Bausch + Lomb and Stevanato Group. Learn More about companies similar to Soleno Therapeutics.

How do I contact Soleno Therapeutics' investor relations team?

Soleno Therapeutics' physical mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company's listed phone number is (650) 213-8444 and its investor relations email address is [email protected]. The official website for Soleno Therapeutics is www.soleno.life. Learn More about contacing Soleno Therapeutics investor relations.